CHICAGO — Fixed-dose combination therapy increased blood pressure control rates from 37% to 76% over 18 months in patients with high-risk hypertension in an ongoing large, multinational trial reported at the annual meeting of the American Society of Hypertension.
Control rates were even higher in the U.S. cohort, where 80.5% of patients achieved control to less than 140 mm Hg—an unprecedented rate for a U.S. trial, reported Dr. Kenneth Jamerson, who presented interim results from the Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial.
Dr. Jamerson and his associates reported significant reductions in systolic blood pressure were seen across all patient populations, including African Americans.
The investigators randomized 11,463 patients who were aged 55 years or more with a systolic blood pressure of at least 160 mm Hg or currently on antihypertensive therapy to treatment with either Lotrel, which contains the ACE inhibitor benazepril and the calcium-channel blocker amlodipine, or to benazepril plus the diuretic hydrochlorothiazide (HCTZ).
At 18 months, patients achieved an average decline in blood pressure from 145/80 mm Hg to 132/74 mm Hg. Almost one-fifth of patients went on to achieve a systolic BP of less than 120 mm Hg. The study remains blinded, so blood pressure reductions were not stratified based on treatment.
Cardiovascular morbidity and mortality outcomes, which are the study's primary end point, are anticipated after the trial ends in 2008.
Dr. Jamerson believes that the current data will help shift the traditional approach to hypertension management in which providers initiate monotherapy then sequentially use additional medications as needed to achieve target blood pressure goals.
“Too many clinicians have chanted the mantra, 'start low, go slow,' despite having lots of data that multiple drugs are going to be necessary to achieve blood pressure control,” said Dr. Jamerson, professor in the department of internal medicine, division of cardiovascular medicine, University of Michigan, Ann Arbor.
“We think we provide substantial evidence to suggest that initial combination therapy is very effective, and think there is substantial evidence to support broadening the use of combination therapy as an initial therapy.”
Although 97% of patients in the study were already taking antihypertensive medication, only 37.5% had their blood pressure controlled at baseline to 140/90 mm Hg—the currently recommended target in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7).
Dosages were titrated at month 2 to a fixed dose of benazepril 40 mg/amlodipine 10 mg or benazepril 40 mg/HCTZ 25 mg, with the option of adding on other antihypertensive agents at month 3. Overall, 35% of patients used add-on medications, said Dr. Jamerson, who has received grant/research support from Novartis, which sponsored the study and markets Lotrel.
At 18 months, the average systolic BP declined from 153 mm Hg to 137 mm Hg among Nordic patients, from 142 mm Hg to 129 among the U.S. cohort, and from 145 mm Hg to 133 mm Hg among African Americans.
A bit more work needs to be done among patients with diabetes and chronic kidney disease, Dr. Jamerson said. Their respective mean systolic BPs decreased from 145 mm Hg to 131.5 mm Hg and from 149 mm Hg to 136 mm Hg—both short of the JNC 7 goal of 130 mm Hg for these difficult-to-treat populations. Overall, 60% of ACCOMPLISH participants have diabetes, and had a BP control rate of 15%.
ASH President Suzanne Oparil said in an interview that these are the highest overall control rates ever achieved, but at roughly 80% are only slightly higher than the 65% reported in previous hypertension trials.
The low systolic BP rates reported in the U.S. cohort may reflect higher values at baseline in the Nordic cohort and a more cautious treatment approach typically used by European physicians.
Dr. Oparil, professor of medicine, physiology, and biophysics at the University of Alabama, Birmingham, took issue with the notion that these results will shift treatment patterns. The VALUE, or Valsartan Antihypertensive Long-term Use Evaluation trial, already provided clinicians with the lesson that controlling blood pressure quickly is important.
“It's not that paradigm shifting because that's what we're preaching anyway,” she said.
Too many have chanted the mantra, 'start low, go slow,' despite having lots of data that multiple drugs are necessary. DR. JAMERSON